Skip to main content

Table 3 List of immunomodulatory antibodies currently in clinical development and their respective isotypes

From: The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

Antibody Target Company Latest active clinical phase Isotype
Ipilimumab CTLA-4 BMS Approved IgG1
Tremelimumab CTLA-4 MedImmune/AstraZeneca II IgG2
Nivolumab PD-1 BMS Approved IgG4
MK-3475 PD-1 Merck III IgG4
CT-011 PD-1 CureTech II IgG1
MPDL3280A PD-L1 Genentech/Roche III Aglycosyl IgG1
MEDI4736 PD-L1 MedImmune/AstraZeneca I IgG1 TM
MDX-1105 PD-L1 BMS I IgG4
MSB0010718C PD-L1 Merck KGaA I IgG1
BMS-663513 CD137 BMS I IgG4
PF-05082566 CD137 Pfizer I IgG2
TRX518 GITR GITR Inc I Aglycosyl IgG1
MEDI6469 OX40 MedImmune/AstraZeneca/AgonOX I Mouse IgG1
CP-870,893 CD40 Roche I IgG2
CDX-1127 CD27 CellDex I IgG1
Lirilumab; IPH2102 KIR BMS/Innate Pharma II IgG4
MGA271 B7-H3 Macrogenics/Servier I IgG1
Alemtuzumab CD52 Genzyme/Bayer Approved IgG1
  1. IgG1 TM = IgG1 triple mutant, which contains 3 point mutations in the Fc domain that reduce the binding affinity of the mAb to FcγRs [30].